These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

587 related articles for article (PubMed ID: 23224399)

  • 21. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
    Lee-Hoeflich ST; Crocker L; Yao E; Pham T; Munroe X; Hoeflich KP; Sliwkowski MX; Stern HM
    Cancer Res; 2008 Jul; 68(14):5878-87. PubMed ID: 18632642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
    Vazquez-Martin A; Oliveras-Ferraros C; Cufí S; Del Barco S; Martin-Castillo B; Menendez JA
    J Cell Physiol; 2011 Jan; 226(1):52-7. PubMed ID: 20658522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib.
    Huang C; Park CC; Hilsenbeck SG; Ward R; Rimawi MF; Wang YC; Shou J; Bissell MJ; Osborne CK; Schiff R
    Breast Cancer Res; 2011 Aug; 13(4):R84. PubMed ID: 21884573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MEK inhibition increases lapatinib sensitivity via modulation of FOXM1.
    Gayle SS; Castellino RC; Buss MC; Nahta R
    Curr Med Chem; 2013; 20(19):2486-99. PubMed ID: 23531216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin.
    Garner AP; Bialucha CU; Sprague ER; Garrett JT; Sheng Q; Li S; Sineshchekova O; Saxena P; Sutton CR; Chen D; Chen Y; Wang H; Liang J; Das R; Mosher R; Gu J; Huang A; Haubst N; Zehetmeier C; Haberl M; Elis W; Kunz C; Heidt AB; Herlihy K; Murtie J; Schuller A; Arteaga CL; Sellers WR; Ettenberg SA
    Cancer Res; 2013 Oct; 73(19):6024-35. PubMed ID: 23928993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts.
    Rimawi MF; Wiechmann LS; Wang YC; Huang C; Migliaccio I; Wu MF; Gutierrez C; Hilsenbeck SG; Arpino G; Massarweh S; Ward R; Soliz R; Osborne CK; Schiff R
    Clin Cancer Res; 2011 Mar; 17(6):1351-61. PubMed ID: 21138857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.
    Larbouret C; Gaborit N; Chardès T; Coelho M; Campigna E; Bascoul-Mollevi C; Mach JP; Azria D; Robert B; Pèlegrin A
    Neoplasia; 2012 Feb; 14(2):121-30. PubMed ID: 22431920
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lapatinib.
    Voigtlaender M; Schneider-Merck T; Trepel M
    Recent Results Cancer Res; 2018; 211():19-44. PubMed ID: 30069757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
    Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
    Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.
    Blancafort A; Giró-Perafita A; Oliveras G; Palomeras S; Turrado C; Campuzano Ò; Carrión-Salip D; Massaguer A; Brugada R; Palafox M; Gómez-Miragaya J; González-Suárez E; Puig T
    PLoS One; 2015; 10(6):e0131241. PubMed ID: 26107737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
    Fichter CD; Timme S; Braun JA; Gudernatsch V; Schöpflin A; Bogatyreva L; Geddert H; Faller G; Klimstra D; Tang L; Hauschke D; Werner M; Lassmann S
    Int J Cancer; 2014 Oct; 135(7):1517-30. PubMed ID: 24510732
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
    O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
    Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib.
    Amin DN; Ruiz-Saenz A; Gulizia N; Moasser MM
    Oncotarget; 2015 Dec; 6(38):41123-33. PubMed ID: 26516700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.